Low-Dose Cytosine Arabinoside in Patients with Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

References

• Toronto leukemia study group., results of chemotherapy for unselected patients with acute myeloblastic leukemia: effect of exclusions on interpretation of results. Lancet 1986; i: 786–788
   Google Scholar
• Wahlin A., Hornsten P., Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur. J. Haematol. 1991; 46(24&247)
   PubMedGoogle Scholar
• Huang M., Yu-Chen Y., Shu-Rong C., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M.T., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiating therapy for acute promyelocytic leukemia I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Grignani F., Fagioli M., Alcalay M., et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Champlin E.R., Gajewski J.L., Golde W. Treatment of acute myelogenous leukemia in the elderly. Semin. Oncol. 1989; 16: 51–56
   PubMed Web of Science ®Google Scholar
• Lowenberg B., Zittoun R., Kerkhofs H., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol. 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Ishikura H., Sawada H., Okazaki T., et al. The effect of low-dose Ard-C in acute nonlymphoblastic leukaemias and atypical lukaemia. Br. J. Hematol. 1984; 58: 9–18
   PubMed Web of Science ®Google Scholar
• Degos L., Castaigne S., Tilly H., Sigaux F., Daniel M.T. Treatment of leukemia with low-dose Ara C: a study of 160 cases. Semin. Oncol. 1985; 12: 196–199, suppl 3
   PubMed Web of Science ®Google Scholar
• Leberger G., Valensi F., Daniel M.T., Schaison G., Bancillon A., Castaigne S. Efficacité de la cytarabine à faibles doses après échec d'une chimiothérapie conventionelle. Presse Med. 1985; 14: 1562
   Google Scholar
• Tilly H., Castaigne S., Bordessoule D., et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 1985; 55: 1633–1636
   PubMed Web of Science ®Google Scholar
• Winter J.N., Variakojis D., Gaynor E.R., Larson R.A., Miller K.B. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer 1985; 56: 443–449
   PubMed Web of Science ®Google Scholar
• Cheson B.D., Jasperse D.M., Simon R., Friedman M A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J. Clin. Oncol. 1986; 4: 1857–1864
   PubMed Web of Science ®Google Scholar
• Jensen M.K., Stentoft J. Low-dose cytosine arabinoside in the treatment of relapsed and refractory acute non-lymphocytic leukemia. Acta Haemat. 1986; 76: 127–129
   PubMed Web of Science ®Google Scholar
• RossiFerrini P., Bernabei P., Leoni F. Low dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia in the elderly. New Trends Ther. Leuk. Lymph. 1986; 1: 75–86
   Google Scholar
• Bolwell B.J., Cassileth P.A., Gale R.P. Low-dose cytosine arabinoside in myelodisplasia and acute mielogenous leukemia. A review. Leukemia 1987; 1: 575–579
   PubMed Web of Science ®Google Scholar
• Powell B.L., Capizzi R.L., Muss H.B., et al. Low-dose Ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 1989; 3: 23–28
   PubMed Web of Science ®Google Scholar
• Rossi Ferrini P., Ciolli S., Leoni F. Low dose cytosine arabinoside in adult acute non-lymphoid leukemia. Bone Marrow Trunsp. 1989; 4: 36–37
   PubMed Web of Science ®Google Scholar
• Tertian G., Tchernia G., Léonard C., et al. Low-dose ara-binosyl cytosine therapy of AML may be effective after failure of high or conventional doses. Nouv. Rev. Fr. Hematol. 1989; 31: 311–313
   PubMedGoogle Scholar
• Tilly H., Castaigne S., Bordessoule D., et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol. 1990; 8: 272–280
   PubMed Web of Science ®Google Scholar
• Detourmignies L., Wattel E., Lai J.L., Bauters F., Fenaux P. Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?. Ann. Hematol. 1993; 66: 235–240
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemias: a report of the French-American-British Co-operative Group. Ann. Int. Med. 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Ellison R.R., Holland J.F., Weil M., et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Foon K.A., Zighelboim J., Yale C., et al. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981; 58: 467–470
   PubMed Web of Science ®Google Scholar
• Liu Yin J.A., Johnson P.R.E., Davies J.M., Flanagan N.G., Gorst D.W., Lewis M.J. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 1991; 79: 415–429
   PubMed Web of Science ®Google Scholar
• Shepherd J.D., Reece D.E., Barnett M.J., et al. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside. mitoxantrone and etoposide. Leuk. Lymph. 1993; 9: 211–215
   PubMed Web of Science ®Google Scholar
• Preisler H.D., Lyman G.H. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical feature and response to therapy. Am. J. Hematol. 1977; 3: 209–218
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F., Catovsky D., Galton D.A.G. Clinical and laboratory features of de novo acute myeloid leukemia with trilineage myelodysplasia. Br. J. Haematol. 1987; 66: 445–450
   PubMed Web of Science ®Google Scholar
• Preisler H. Poor prognosis acute myelogenous leukemia. Leuk. Lymph. 1993; 9: 273–283
   PubMed Web of Science ®Google Scholar
• Cuneo A., van Orshoven A., Michaux J.L., et al. Morphologic, immunologic and cytogenetic studies in erythroleukemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Br. J. Haematol. 1990; 75: 346–354
   PubMed Web of Science ®Google Scholar
• Atkinson J., Hrisinko M.A., Weil S.C. Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature. Blood Rev. 1993; 6: 204–214
   Web of Science ®Google Scholar
• Ruiz-Argüelles G.J., Marin-Lopez A., Lobato-Mendizabal E., Ruiz-Arguelles A., Nichols W.L., Katzmann J.A. Acute megakaryoblastic leukaemia: a prospective study of its identification and treatment. Br. J. Haematol. 1986; 62: 55–63
   PubMed Web of Science ®Google Scholar
• San-Miguel J.F., Gonzales M., Canizo M.C., et al. Leukemias with megakaryoblastic involvement. Clinical, hematologic and immunologic characteristics. Blood 1988; 72: 402–407
   PubMed Web of Science ®Google Scholar
• Mertelsmann R., Thaler H.T., To L., et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773–781
   PubMed Web of Science ®Google Scholar
• Champlin R., Gale R.P. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551–1562
   PubMed Web of Science ®Google Scholar
• Lutz D., Kieger O., Ihle R., et al. Different response rates to low-dose cytosine arabinoside in acute myeloid leukemia subtypes. Semin. Oncol. 1987; 14: 121–125
   PubMed Web of Science ®Google Scholar
• Balaban E.P., Cox J.V., Schneider N.R., et al. Treatment of “poor risk” acute nonlymphocytic leukemia with continously infused low-dose cytosine arabinoside. Am. J. Hematol. 1988; 29: 79–84
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Robert K.H., et al. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br. J. Haematol. 1992; 81: 503–511
   PubMed Web of Science ®Google Scholar
• Ciolli S., Leoni F., Giuliani G., et al. Idarubicin on alternate days in AML of the elderly: a clinical and pharmacokinetic study. Blood 1993; 82: 536a
   Google Scholar
• Manoharan A. Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients-a pilot study. Aust. NZ. J. Med. 1992; 22: 710
   PubMedGoogle Scholar